drugset / Trial / NCT05495321
Interleukin-2 on Active Dermatomyositis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2025-09-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |